Product DescriptionMouse anti-Lipid phosphate phosphohydrolase 3 (LPP3) Monoclonal Antibody (Unconjugated), suitable for WB, FC.
Application DetailsWestern Blotting (WB), Flow cytometry (FACS) and Immunohistochemistry (IHC). For WB, the recommended concentration is 2-3 µg/mL. For IHC, this antibody has been shown to work on formalin-fixed, paraffin-embedded tissue samples with heat-induced antigen retrieval. The recommended concentration is 0.5-2 µg/mL. For FACS, the recommended concentration is 2.0 µg/mL. Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
TargetLipid phosphate phosphohydrolase 3 (LPP3)
SpecificityConfirmed by over-expression of human LPP3 cDNA. Human
Target Host SpeciesHuman
Antibody IsotypeMix of IgG1, IgG2a & IgG2b
Immunogen DescriptionA synthetic peptide from human LPP3 (179-196 aa) conjugated to KLH.
Purity DescriptionAffinity purified
FormatLyophilized from PBS pH 7.4
Reconstitution InstructionsSpin vial briefly before opening. Reconstitute in 100 uL sterile-filtered, ultrapure water. Centrifuge to remove any insoluble material.
Storage InstructionsAt least 12 months after purchase at 2-8°C (lyophilized formulations). After reconstitution, aliquot and store at -20°C for a higher stability and at 2-8°C with an appropriate antibacterial agent. Avoid freeze-thaw cycles.
Batch NumberPlease see item label.
Expiration Date12 months after date of receipt (unopened vial).
Alternative NamesLipid phosphate phosphohydrolase 3; PAP2-beta; Phosphatidate phosphohydrolase type 2b; Phosphatidic acid phosphatase 2b; PAP-2b; PAP2b; Vascular endothelial growth factor and type I collagen-inducible protein; VCIP; PPAP2B;LPP3
Scientific BackgroundLipid phosphate phosphohydrolase 3 (LPP3) is a member of the phosphatidic acid phosphatase (PAP) family. LPP3 catalyzes the conversion of phosphatidic acid to diacylglycerol. In addition it hydrolyzes lysophosphatidic acid, ceramide-1-phosphate and sphingosine-1-phosphate (Ref: SWISSPROT).
Specific ReferencesMueller PA (2016) PPAP2B expression limits lesion formation in murine models of atherosclerosis. Doctoral Dissertation. Species: Mouse. Application: IHC.
Reschen ME, Gaulton KJ, Lin D, Soilleux EJ, Morris AJ, Smyth SS and O'Callaghan CA (2015) Lipid-induced epigenomic changes in human macrophages identify a coronary artery disease-associated variant that regulates PPAP2B Expression through Altered C/EBP-beta binding. PLoS Genet. 2015 Apr 2;11(4):e1005061. Species: Human. Application: IHC with heat-induced antigen retrieval.
Humtsoe JO, Liu M, Malik AB and Wary KK (2010) Lipid phosphate phosphatase 3 stabilization of beta-catenin induces endothelial cell migration and formation of branching point structures. Mol Cell Biol. Apr;30(7):1593-606. Species: Human. Application: WB and IHC.